Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:CGON NASDAQ:IMVT NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.05+2.2%$2.95$1.52▼$4.08$807.35M0.683.95 million shs502,470 shsCGONCG Oncology$43.33+3.2%$35.13$14.80▼$45.56$3.30B1.31986,577 shs206,649 shsIMVTImmunovant$18.95+1.1%$16.19$12.72▼$32.10$3.30B0.481.52 million shs135,743 shsXENEXenon Pharmaceuticals$41.37+0.4%$38.86$26.74▼$46.00$3.19B1.14857,498 shs256,658 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-0.33%+2.05%+5.30%-16.29%+87.42%CGONCG Oncology+0.17%+0.31%+14.39%+60.84%+17.89%IMVTImmunovant-0.85%+7.64%+25.77%+10.56%-37.57%XENEXenon Pharmaceuticals-2.32%-2.30%+10.43%+35.97%-1.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.05+2.2%$2.95$1.52▼$4.08$807.35M0.683.95 million shs502,470 shsCGONCG Oncology$43.33+3.2%$35.13$14.80▼$45.56$3.30B1.31986,577 shs206,649 shsIMVTImmunovant$18.95+1.1%$16.19$12.72▼$32.10$3.30B0.481.52 million shs135,743 shsXENEXenon Pharmaceuticals$41.37+0.4%$38.86$26.74▼$46.00$3.19B1.14857,498 shs256,658 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-0.33%+2.05%+5.30%-16.29%+87.42%CGONCG Oncology+0.17%+0.31%+14.39%+60.84%+17.89%IMVTImmunovant-0.85%+7.64%+25.77%+10.56%-37.57%XENEXenon Pharmaceuticals-2.32%-2.30%+10.43%+35.97%-1.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.71Moderate Buy$6.75126.51% UpsideCGONCG Oncology 2.77Moderate Buy$58.7039.83% UpsideIMVTImmunovant 2.58Moderate Buy$28.7853.56% UpsideXENEXenon Pharmaceuticals 2.92Moderate Buy$53.6730.26% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, IMVT, XENE, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025IMVTImmunovantTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$16.0010/14/2025IMVTImmunovantWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025XENEXenon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGONCG OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025CGONCG OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.0010/7/2025CGONCG OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.0010/7/2025XENEXenon PharmaceuticalsBloom BurtonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/7/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.009/30/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$37.00 ➝ $33.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M4.93N/AN/A($0.23) per share-12.96CGONCG Oncology$1.14M2,807.87N/AN/A$9.63 per share4.36IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AXENEXenon Pharmaceuticals$9.43M336.90N/AN/A$9.90 per share4.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)CGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest AKBA, IMVT, XENE, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CGONCG Oncology-$0.57N/AN/AN/A$0.07 millionN/A11/11/2025Q3 2025XENEXenon Pharmaceuticals-$1.16N/AN/AN/AN/AN/A11/6/2025Q3 2025AKBAAkebia Therapeutics-$0.02N/AN/AN/A$52.06 millionN/A11/6/2025Q2 2026IMVTImmunovant-$0.73N/AN/AN/AN/AN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84CGONCG OncologyN/A22.1522.15IMVTImmunovantN/A12.3212.32XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CGONCG Oncology26.56%IMVTImmunovant47.08%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CGONCG Oncology7.40%IMVTImmunovant1.80%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableCGONCG Oncology6176.25 million70.61 millionOptionableIMVTImmunovant120174.32 million171.18 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableAKBA, IMVT, XENE, and CGON HeadlinesRecent News About These CompaniesStifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)October 23 at 7:31 AM | theglobeandmail.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 18, 2025 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 18, 2025 | marketbeat.comXenon Pharmaceuticals appoints Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | msn.comXenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization EffortsOctober 16, 2025 | tipranks.comXenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of AzetukalnerOctober 16, 2025 | quiverquant.comQXenon Announces Appointment of Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | globenewswire.comXenon (XENE) Receives a Buy from JefferiesOctober 16, 2025 | theglobeandmail.comXenon Pharmaceuticals (NASDAQ:XENE) Earns "Sell (D-)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comInvestors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)October 16, 2025 | marketbeat.comAberdeen Group plc Boosts Position in Xenon Pharmaceuticals Inc. $XENEOctober 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Sell (D-)" Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comXenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price MomentumOctober 12, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for XENE FY2025 EarningsOctober 10, 2025 | marketbeat.comBrokers Offer Predictions for XENE FY2026 EarningsOctober 8, 2025 | marketbeat.comBloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy"October 8, 2025 | marketbeat.comChardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy RecommendationOctober 7, 2025 | msn.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | globenewswire.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William BlairOctober 7, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan CapitalOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, IMVT, XENE, and CGON Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.04 +0.07 (+2.18%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CG Oncology NASDAQ:CGON$43.32 +1.35 (+3.20%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Immunovant NASDAQ:IMVT$18.95 +0.21 (+1.12%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Xenon Pharmaceuticals NASDAQ:XENE$41.37 +0.17 (+0.41%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
